@article{mbs:/content/journal/jgv/10.1099/0022-1317-83-6-1377, author = "Kano, Munehide and Matano, Tetsuro and Kato, Atsushi and Nakamura, Hiromi and Takeda, Akiko and Suzaki, Yuriko and Ami, Yasushi and Terao, Keiji and Nagai, Yoshiyuki", title = "Primary replication of a recombinant Sendai virus vector in macaques", journal= "Journal of General Virology", year = "2002", volume = "83", number = "6", pages = "1377-1386", doi = "https://doi.org/10.1099/0022-1317-83-6-1377", url = "https://www.microbiologyresearch.org/content/journal/jgv/10.1099/0022-1317-83-6-1377", publisher = "Microbiology Society", issn = "1465-2099", type = "Journal Article", abstract = "An efficient antigen expression system using a recombinant Sendai virus (SeV) has been established recently and its potential to induce resistance against immunodeficiency virus infections in macaques has been shown. SeV replication has been well characterized in mice, the natural host, but not in primates, including humans. Here, primary SeV replication was investigated in macaques. After intranasal immunization with a recombinant SeV expressing simian immunodeficiency virus Gag protein, SeV-Gag, robust gag expression was observed in the nasal mucosa and much lower but significant levels of gag expression were observed in the local retropharyngeal and submandibular lymph nodes (LN). Expression peaked within a week and lasted at least up to 13 days after immunization. SeV-Gag was isolated from nasal swabs consistently at day 4 but not at all at day 13. Gag expression was undetectable in the lung as well as in remote lymphoid tissues, such as the thymus, spleen and inguinal LN, indicating that the spread of the virus was more restricted in macaques than in mice. SeV-specific T cells were detectable in SeV-immunized macaques at day 7. Finally, no naive macaques showed significant levels of anti-SeV antibodies in the plasma, even after living in a cage together with an acutely SeV-infected macaque for 5 weeks, indicating that SeV transmission from SeV-infected macaques to naive ones was inefficient. None of the SeV-immunized macaques displayed appreciable clinical manifestations. These results support the idea that this system may be used safely in primates, including humans.", }